Navigation Links
Judge Denies Medtronic’s Bid to Dismiss Lawsuit Alleging that the Off-Label Usage of its Infuse Bone Growth Product Caused Disability, Parker Waichman LLP Notes
Date:7/25/2013

New York, New York (PRWEB) July 25, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective medical devices, notes that a Plaintiff's lawsuit alleging that the off-label use of Medtronic’s Infuse bone graft product had caused him to be permanently disabled will proceed. The Judge has denied Medtronic’s bid to have the lawsuit overturned, according to court papers. The suit was filed on Jan. 10, 2013, in the Circuit Court of Cook County, Ill. (Case No.: 2013-L-000305).

According to the Complaint, the Plaintiff had been diagnosed with problems in his cervical spine and, as a result, was given a posterior cervical fusion in 2011. This, the Complaint noted, represented an off-label use of the product because the U.S. Food and Drug Administration (FDA) had not approved Infuse to be used in cervical procedures.

Parker Waichman LLP is reporting that it continues to investigate allegations of people who claim they were harmed by the product. Such allegations are not limited to the off-label use of Medtronic’s Infuse. In fact, two independent studies* published in the June edition of the medical journal Annals of Internal Medicine call into question Infuse’s overall level of effectiveness, as well as highlight potential harm the product can cause.

(*http://annals.org/article.aspx?articleid=1696646; http://annals.org/article.aspx?articleid=1696645)

The two independent studies, overseen by Yale University, reveal important key findings regarding Medtronic’s Infuse product—namely, that there is little, if any, difference in the effectiveness of Infuse over a traditional bone graft. Additionally, Infuse has the potential to cause harmful, if not fatal, side effects, including:

  •     Retrograde ejaculation
  •     Cancer
  •     Pain
  •     Extraneous bone growth.

Medtronic approached Yale University researchers after a June 2011 study published in The Spine Journal disclosed that Medtronic-paid researchers had failed to report serious potential complications from use of Infuse bone graft products in spinal surgery.

Infuse was approved by the FDA in 2002, explicitly for use in a single type of spinal surgery that involves fusing together vertebrae in the lower spine, with the surgeon using a frontal approach. But it became widely used off-label—meaning for uses not officially approved by the FDA. On July 8, 2008, the FDA issued a safety alert to warn about the use of Infuse in the upper spine and the neck region after receiving dozens of reports of serious side effects associated with such use of the device. Among the side effects due to off-label use, according to the FDA, are:

  •     Swelling of neck and throat tissue, resulting in compression of the airway and/or neurological structures in the neck
  •     Difficulty swallowing, breathing or speaking
  •     Nerve damage
  •     Severe dysphagia

The FDA also noted in the 2008 safety alert that, since 2004, it had received nearly 40 reports of complications arising from the off-label use of Infuse in cervical spine fusion. The FDA highlighted the fact that “[w]hen airway complications occurred, medical intervention was frequently necessary. Treatments needed included respiratory support with intubation, anti-inflammatory medication, tracheotomies and, most commonly, second surgeries to drain the surgical site.”

Parker Waichman LLP is currently offering free legal consultations to victims of Medtronic Infuse Bone Graft Injuries. If you or a loved one suffered a serious complication or injury after receiving Medtronic Infuse, please contact their office by visiting the firm's Medtronic Infuse injury page at yourlawyer.com. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/medtronic_lawsuit/07/prweb10966387.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Anorexics Cant Judge Own Body Size: Study
2. New study suggests that same-sex parents are judged more harshly than heterosexual parents
3. DrugRisk Update: Mirena Maker Asks to Keep Lawsuits With Local Court, Judge
4. Johnson & Johnson Ethicon Transvaginal Mesh Lawsuits Update: Resource4thePeople Reports Judge Schedules More Trials for This Summer
5. Judge: Make Morning-After Pill Available to All Females
6. Work By Female Scientists Gets Judged More Harshly: Study
7. Presence Technology Chosen to Judge Startup World’s First Visit to Spain
8. Obama Administration to Challenge Judges Ruling on Morning-After Pill
9. NuvaRing Lawsuits Move Forward, as Federal Judge Rules that Plaintiffs’ Experts May Testify on “Bursts” of Estrogen Allegedly Delivered by NuvaRing, Wright & Schulte LLC
10. Actos Lawyers at Bernstein Liebhard LLP Comment on California Judge’s Decision to Set Aside Verdict in Nation’s First Actos Bladder Cancer Trial
11. NuvaRing Lawsuit News: Rottenstein Law Group Responds to Judge’s Refusal to Dismiss Punitive Damages Claims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Doylestown, Pa. (PRWEB) , ... ... ... leading provider of technology-enabled clinical trial solutions, today announced the further expansion ... types of applications they can leverage as part of Bioclinica’s extensive and ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article ... weight loss. It found that the treatments have led to significant improvements in weight ... to unassisted efforts. It also noted very few problematic results relating to the treatment. ...
(Date:2/20/2017)... ... February 21, 2017 , ... Nancy Johnston Toll marks her debut ... Getting Over the Bump in the Road ” (published by Xlibris). Inspired from her ... cope with the ups and downs experienced by anyone going through cancer treatment and ...
(Date:2/20/2017)... ... February 20, 2017 , ... Researchers at the University of ... well as a marker that may predict response to a particular class of drugs, ... of cancer as well. The new findings were published in Proceedings of the National ...
(Date:2/20/2017)... ... 2017 , ... Best Doctors® and IBM today announced that ... that want to help members of their workforce battling cancer. Through the Best ... suite of oncology offerings for insights on cancer treatment options, ranging from standard ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Lexmark International, ... solution that connects Lexmark multifunction printers (MFPs) to EDCO ... leading scanning and indexing software solutions for medical records. ... use a Lexmark MFP at the point of care ... facilities reach HIMSS Stage 7 through state-of-the-art ...
(Date:2/21/2017)... IDAHO FALLS, Idaho , Feb. 21, 2017 /PRNewswire/ ... is has completed a private placement with certain investors ... preferred stock of the Company, Series C Convertible Redeemable ... Stock accrues dividends at an annual rate of 6% ... share.  The Company plans to use the proceeds for ...
(Date:2/21/2017)... SAN JOSE, Calif. , Feb. 21, 2017 ... announced that its Cadence ® Tensilica ® Fusion ... HaLow ™ MAC IP offering. The licensable IP targets ... smart city and industrial applications. M2B leveraged the Fusion F1 ... to run value-added applications like voice trigger, audio identification and ...
Breaking Medicine Technology: